skip to main content

Prostate Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardUrological CancersProstate CancerSCE Medical Oncology

A 73-year-old man has newly diagnosed low-volume metastatic hormone-sensitive prostate cancer. He is medically fit for docetaxel but declines intravenous chemotherapy after informed discussion. He does not meet a high-risk-only abiraterone criterion. Which oral intensification has a NICE recommendation that does not depend on docetaxel being unsuitable or on high-risk disease?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Enzalutamide plus continued androgen-deprivation therapy as oral systemic intensification

TA712 recommends enzalutamide with ADT for hormone-sensitive metastatic prostate cancer without restricting the recommendation by disease volume, high-risk features or docetaxel unsuitability. Apalutamide TA741 is framed for people in whom docetaxel is unsuitable, while abiraterone funding criteria are not established merely by low-volume metastatic disease. ADT must continue with an androgen-receptor inhibitor, and declining chemotherapy does not justify undertreatment with ADT alone.

Reference: NICE TA712 enzalutamide for hormone-sensitive metastatic prostate cancer (Published July 2021): https://www.nice.org.uk/guidance/ta712/chapter/1-Recommendations